NCT03207009View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 8, 2017

Primary Completion Date

November 15, 2022

Study Completion Date

November 15, 2022

Conditions
Beta-Thalassemia
Interventions
GENETIC

LentiGlobin BB305 Drug Product

LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.

Trial Locations (9)

13385

Hopital d'enfants de la Timone, Marseille

19104

Children's Hospital of Philadelphia, Philadelphia

30625

Hannover Medical School, Hanover

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

69120

University of Heidelberg, Heidelberg

94609

UCSF Benioff Children's Hospital Oakland, Oakland

Unknown

General Hospital of Thessaloniki 'G.Papanikolaou', Thessaloniki

IRCCS Ospedale Pediatrico Babino Gesu, Rome

University College London Hospital, London

Sponsors
All Listed Sponsors
lead

Genetix Biotherapeutics Inc.

INDUSTRY

NCT03207009 - A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia | Biotech Hunter | Biotech Hunter